- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Curis Inc (CRIS)
Curis Inc stock price live, this page displays NASDAQ CRIS stock exchange data. View the CRIS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Curis Inc real time stock price chart below.
What Is the Curis Inc Stock Price Today?
The Curis Inc stock price today is 1.6700.
What Is the Stock Symbol for Curis Inc?
The stock symbol for Curis Inc is ""CRIS.""
What Stock Exchange Does Curis Inc Trade On?
Curis Inc is listed and trades on the NASDAQ stock exchange.
Is Curis Inc a Good Stock to Buy?
Determining whether Curis Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CRIS quote. (ISIN: US2312693094)
What Is the Curis Inc Stock Price Today?
The Curis Inc stock price today is 1.6700.
What Is the Stock Symbol for Curis Inc?
The stock symbol for Curis Inc is ""CRIS.""
What Stock Exchange Does Curis Inc Trade On?
Curis Inc is listed and trades on the NASDAQ stock exchange.
Is Curis Inc a Good Stock to Buy?
Determining whether Curis Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CRIS quote. (ISIN: US2312693094)
NASDAQ
Currency in USD
Fair Value
An estimate of a Curis's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.6400
1.7400
52 wk Range
1.0200
6.4600
CRIS Scorecard
Full Analysis
2 analysts have revised their earnings upwards for the upcoming period
CRIS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Curis's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.64001.7400
52 wk Range
1.02006.4600
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CRIS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Curis's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
16.3333
Upside
+878.04%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
- Form 10Q Curis Inc For: 5 August
- Investing.com
- Form 10Q Curis Inc For: 5 August
- Investing.com
- Form 8K Curis Inc For: 2 July
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell
Curis Inc Company Profile
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Curis Inc Earnings Call Summary for Q2/2025
- Curis Inc's Q2 2025 net loss reduced to $8.6M ($0.68/share) from $11.8M ($2.03/share) in Q2 2024; stock rose 10% to $1.76 in premarket trading
- Cash runway extended into 2026 after $6M offering; R&D and administrative expenses decreased significantly year-over-year
- Company to present AML triplet study data at ASH conference in December; plans to initiate CLL study by year-end with initial data expected mid-2026
- CEO highlighted commitment to improving oncology care, but expressed concern over FDA regulatory uncertainty
- Analysts bullish despite weak Financial Health Score; price targets range from $12 to $20 per share
Last Updated: 05/08/2025, 17:00
Read Full TranscriptCompare CRIS to Peers and Sector
Metrics to compare | CRIS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCRISPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.5x | −1.5x | −0.6x | |
PEG Ratio | −0.01 | 0.00 | 0.00 | |
Price/Book | −1.5x | 1.0x | 2.6x | |
Price / LTM Sales | 1.8x | 45.8x | 3.3x | |
Upside (Analyst Target) | - | 195.2% | 39.0% | |
Fair Value Upside | Unlock | 26.2% | 4.9% | Unlock |
Analyst Ratings
5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 16.3333
(+878.04% Upside)
Earnings
Latest Release
Aug 05, 2025
EPS / Forecast
-0.68 / -1.24
Revenue / Forecast
2.75M / --
People Also Watch
FAQ
What Stock Exchange Does Curis Trade On?
Curis is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Curis?
The stock symbol for Curis is "CRIS."
What Is the Curis Market Cap?
As of today, Curis market cap is 21.00M.
What Is Curis's Earnings Per Share (TTM)?
The Curis EPS (TTM) is -4.48.
From a Technical Analysis Perspective, Is CRIS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Curis Stock Split?
Curis has split 2 times.
How Many Employees Does Curis Have?
Curis has 34 employees.
What is the current trading status of Curis (CRIS)?
As of 26 Aug 2025, Curis (CRIS) is trading at a price of 1.67, with a previous close of 1.65. The stock has fluctuated within a day range of 1.64 to 1.74, while its 52-week range spans from 1.02 to 6.46.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.